TC BioPharm

About TC BioPharm

TC BioPharm is a pioneer in developing the first scalable 'off the shelf' allogeneic gamma delta T cell therapy platform, aimed at revolutionizing the treatment of cancer and infectious diseases with fewer side effects, broader application, and efficient manufacturing processes.

Products & Services

Gamma Delta T Cell Therapy:An allogeneic therapy platform focusing on treating cancer and infectious diseases with reduced side effects and no off-tumor toxicity.

Cell Banks:Off-the-shelf solutions to treat more patients efficiently.

Co-Stim CAR-T:A therapy approach designed to minimize side effects through targeted treatment.

Integrated Model:A streamlined approach to product development, clinical translation, and manufacturing for efficient drug delivery.

Specialties

Allogeneic Gamma Delta T Cell Therapy Cancer Treatment Infectious Disease Treatment Cell and Gene Manufacturing Clinical Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-dilutive Grant T: - FT: Non-dilutive Grant	A: 250000 MR: - FA: $250,000 FAN: 250000	D: 2024-11-12 FD: 2024-11-12	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 6000000 MR: - FA: 6.0 million FAN: 6000000	D: 2024-08-28 FD: 2024-08-28	-
3	RT: Public Offering T: - FT: Public Offering	A: 2000000 MR: - FA: 2.0 million FAN: 2000000	D: 2024-08-15 FD: 2024-08-15	-
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 2000000 MR: - FA: $2.0 million FAN: 2000000	D: 2024-08-13 FD: 2024-08-13	1 investors
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3875000 MR: - FA: £3.1 million FAN: 3875000	D: 2024-05-06 FD: 2024-05-06	1 investors
6	RT: Series D Warrants Exercise T: - FT: Series D Warrants Exercise	A: 1263000 MR: - FA: $1.26 M FAN: 1263000	D: 2024-03-18 FD: 2024-03-18	1 investors
7	RT: Public Offering T: - FT: Public Offering	A: 3500000 MR: - FA: $3.5 million FAN: 3500000	D: 2023-12-22 FD: 2023-12-22	1 investors
8	RT: Public Offering T: - FT: Public Offering	A: 3500000 MR: - FA: $3.5 million FAN: 3500000	D: 2023-12-19 FD: 2023-12-19	1 investors
9	RT: Public Offering T: - FT: Public Offering	A: 5500000 MR: - FA: 5.5 Million FAN: 5500000	D: 2023-03-30 FD: 2023-03-30	-
10	RT: Public Offering T: - FT: Public Offering	A: 5500000 MR: - FA: $5.5 million FAN: 5500000	D: 2023-03-28 FD: 2023-03-28	1 investors

Non-dilutive Grant Latest

2024-11-12

$250K

3 investors (Pro only)

Public Offering 2024-08-28

$6.0M

Public Offering 2024-08-15

$2.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Bryan Kobel

Chief Executive Officer and Board Director

M

Martin Thorp

Chief Financial Officer and Board Director

Recent News

TC BioPharm Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised